Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. - Wikidata - awgldk - TriplyDB

Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

http://www.wikidata.org/entity/Q30513760

about

Ascorbic acid for the treatment of Charcot-Marie-Tooth disease Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach Vincristine-induced peripheral neuropathy in pediatric cancer patients A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene.CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.Symmetry of foot alignment and ankle flexibility in paediatric Charcot-Marie-Tooth disease.A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene.Gait and Lower Limb Observation of Paediatrics (GALLOP): development of a consensus based paediatric podiatry and physiotherapy standardised recording proforma.Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study.Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth disease.High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial Flexor digitorum superficialis opposition tendon transfer improves hand function in children with Charcot-Marie-Tooth disease: case series Is tibialis anterior tendon transfer effective for recurrent clubfoot?Therapeutic options in Charcot-Marie-Tooth diseases.Nine-hole Peg Test and Ten-meter Walk Test for Evaluating Functional Loss in Chinese Charcot-Marie-Tooth Disease Gait in children and adolescents with Charcot-Marie-Tooth disease: a systematic review.Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease.Clinimetric properties of lower limb neurological impairment tests for children and young people with a neurological condition: A systematic review.Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy.A cross-sectional multicenter study of osteogenesis imperfecta in North America - results from the linked clinical research centers.A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study.Measuring disease progression in giant axonal neuropathy: implications for clinical trial design.Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy.Natural history of Charcot-Marie-Tooth disease during childhood.Blink reflex role in algorithmic genetic testing of inherited polyneuropathies.Established and novel measures of upper limb impairment in children with Charcot-Marie-tooth disease type 1A and riboflavin transporter deficiency type 2.Treating pediatric neuromuscular disorders: The future is now.Traduction française de l'échelle Charcot-Marie-Tooth Disease Pediatric Scale.Dejerine-Sottas disease in childhood-Genetic and sonographic heterogeneity.The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM)

P2860

Q24187132-4A2E7666-06E5-4625-91A8-A4AA7CE2F359 Q26768401-F7497301-70EC-4E93-B36C-F6A877961D37 Q28078232-B5F0889C-ED42-4460-BD98-B6E48F7CC636 Q30537559-E2E57D29-8AFB-40A4-BDB5-2735601638B3 Q35891892-B21EB346-3D41-45F6-9940-AF3587D7D6C3 Q36074257-D40EDF98-E48D-4DAE-9D90-053C051D989B Q36251291-3C309346-7E0E-4A8C-AC36-74A25F5EFDAA Q36276587-DDF56B67-D4D8-4943-A8D7-6EA0B1593EC1 Q36651847-B9C775FB-A8A2-4F2A-A9C6-9E5BF13E9B54 Q37000938-E350063F-B928-4B88-A79A-71E60729DBEE Q37021766-E1E9EFF3-4665-4D41-ABB3-13A9710E15DE Q37028358-D1DD2DFC-A37C-4CF5-8BAE-7AF410E48F09 Q37035933-FF067489-1955-4CCE-8AFD-C1DF0D0CD413 Q37118241-EE997883-DB35-4B5E-8EAE-63816817F4C6 Q37443569-668216DB-089C-42CA-8AA8-DAE4480DA897 Q37472462-A20A2353-4F7F-4BB9-B73E-3182F9760B93 Q38363677-829CED09-C421-4DE6-A838-5CAF75F65D6B Q38658209-FA4A507A-DE89-4389-96FD-0D6EB64456B8 Q38832364-DB91F804-3A82-440D-9D88-C6A080B3ADC2 Q38979315-23A68850-9990-456D-A47F-875E9668439E Q39411184-2B98C732-6A80-4A2D-AE41-32B5C9E82F52 Q40991752-1DB848DF-F63A-42C9-AB17-20038AE15B17 Q41141416-3A03D054-C2E5-4C9F-AEB3-27729F96D0BE Q41708271-2CD51761-82EB-4316-AAE7-7621EECCF4B1 Q45868220-5786E4D5-E92C-4159-85E3-6BB6193AFD22 Q47299254-9ACA2011-98C3-4297-B775-9B756E7BBFB9 Q47670751-D868E322-A506-4210-95C2-D51E2AE4C041 Q48156867-293C0274-26C3-4243-841B-3C63ED7DC379 Q49719915-8540A107-9B69-4932-9C54-D44AF19D91A0 Q52756417-8E146D19-F5AD-4744-AF66-A12336574E14 Q53108544-786CFDE4-17E9-4A7A-A88F-0502264E985F Q54986191-24E727EF-D988-46DA-950E-BA0DEFC5D695 Q57291681-82CFC573-7C42-4951-878A-90CED9BD722E

P2860

Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

http://www.wikidata.org/entity/Q30513760

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Validation of the Charcot-Mari ...... outcome measure of disability.

@ast

Validation of the Charcot-Mari ...... outcome measure of disability.

@en

type

label

Validation of the Charcot-Mari ...... outcome measure of disability.

@ast

Validation of the Charcot-Mari ...... outcome measure of disability.

@en

prefLabel

Validation of the Charcot-Mari ...... outcome measure of disability.

@ast

Validation of the Charcot-Mari ...... outcome measure of disability.

@en

P1433

Q30513760-08AAF497-9C4C-447A-84C5-2F31EB701622

P1476

Q30513760-A72BF3E6-799C-494F-B810-D0C0D44149A4

P2093

Q30513760-07F7FD86-3096-4544-9279-A2C1EAB46FF5

Q30513760-266DC5A2-35AF-40A9-92E3-3627E0C37D80

Q30513760-2DE7D600-1BA1-429B-939F-D939769D75EC

Q30513760-61E9CE7C-DD05-4C92-BDE3-4C7B893A0907

Q30513760-642FC537-7C32-4700-BB3D-C6DFE35394EE

Q30513760-70665B7D-671D-42F4-A1FC-18E6BCA145B4

Q30513760-8533350A-42F3-47CB-B01E-4324202F97F6

Q30513760-C70BED73-9187-4756-9445-FD779F4749E1

Q30513760-C73622F8-30CF-4E24-8569-2D3D8F806846

Q30513760-E9E90664-37E7-4473-9A17-FCC8D705E847

P2860

Q30513760-01D1D868-853C-4A84-9114-A7A8C614EB7D

Q30513760-0AB53B6F-D051-476F-BCAE-F40D337D0F75

Q30513760-2381D4BA-6F55-48E3-B591-59C0DA03AA1B

Q30513760-2C78F79D-48DF-4C73-BA14-59F4087843D7

Q30513760-40532354-09DF-43C1-958D-B618BFA76D02

Q30513760-410D5C95-11BC-436A-A57B-9B20A4AABCB9

Q30513760-44766E41-573C-40D8-B8B0-0227F9C9461F

Q30513760-54B5D12F-675C-47EE-9F32-836DF4C74679

Q30513760-5DAE6AF0-CE0F-41E2-8346-DDD437F68AE1

Q30513760-5F6408D9-10AB-4AB7-B4B6-2483D25D0A3C

P304

Q30513760-2DA8F04D-D480-4AF9-AA70-A78C5DA99520

P31

Q30513760-5CAF563B-86AD-4CB5-8386-13795A33C09F

P356

Q30513760-1268C253-5FE8-44AF-9137-FE1BD9E15BB0

P433

Q30513760-59C26B0A-9385-4D46-BC10-300605FE9423

P478

Q30513760-00BE3ECB-C65B-451C-BB0A-979770B54EE5

P577

Q30513760-8376D5AF-AEC5-4C99-8D47-F1AE5F3421DA

P5875

Q30513760-1BBC3434-513A-47D3-B8AB-52F251030CD7

P698

Q30513760-E0BD9774-BE1E-469E-BFD8-D2A8D730AA93

P921

Q30513760-C74C4A67-C471-4FD5-A774-F80B1BCA9E95

P932

Q30513760-4D85FBD7-2E7B-4B74-9F38-D60029F21D9F

P356

P1433

Annals of Neurology

P1476

Validation of the Charcot-Mari ...... outcome measure of disability.

@en

P2093

Davide Pareyson

http://www.w3.org/2001/XMLSchema#string

Francesco Muntoni

http://www.w3.org/2001/XMLSchema#string

Gyula Acsadi

http://www.w3.org/2001/XMLSchema#string

Joshua Burns

http://www.w3.org/2001/XMLSchema#string

Julie F Pallant

http://www.w3.org/2001/XMLSchema#string

Mary M Reilly

http://www.w3.org/2001/XMLSchema#string

Matilde Laurá

http://www.w3.org/2001/XMLSchema#string

Michael E Shy

http://www.w3.org/2001/XMLSchema#string

Monkol Lek

http://www.w3.org/2001/XMLSchema#string

Richard S Finkel

http://www.w3.org/2001/XMLSchema#string

P2860

Normative values for the Foot Posture Index

Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

Isometric muscle torque in children 5 to 15 years of age: normative data.

Two knees or one person: data analysis strategies for paired joints or organs.

Charcot-Marie-Tooth disease subtypes and genetic testing strategies

MFN2 mutations cause severe phenotypes in most patients with CMT2A.

Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Changes in hip and ankle range of motion and hip muscle strength in 8-11 year old novice female ballet dancers and controls: a 12 month follow up study.

Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.

Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations.

P304

642-652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.23572

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224811014

http://www.w3.org/2001/XMLSchema#string

P698

22522479

http://www.w3.org/2001/XMLSchema#string

P921

P932

3335189

http://www.w3.org/2001/XMLSchema#string